Details of the SBP
| General Information of Synthetic Binding Protein (SBP) (ID: SBP000139) | ||||||
|---|---|---|---|---|---|---|
| SBP Name |
BiTE Solitomab
|
|||||
| Synonyms |
Solitumomab; AMG-110; AMG110; MT110
|
|||||
| Design Method | Traditional methods (Site-directed mutagenesis and/or Directed evolution) | |||||
| Expression System | Chinese hamster ovary cells | |||||
| Highest Status | Phase II | |||||
| Protein Scaffold Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| Scaffold ID | PS018 | [1] , [2] | ||||
| Scaffold Name | BiTE | |||||
| Scaffold Class | Antibody fragment | |||||
| Fold Type | Beta-Sheets + Loops | |||||
| Binding Target(s) of This SBP (BTS) |
|---|
| BTS Name | Details | Mechanism | Application | Affinity | Research Organization | Ref |
|---|---|---|---|---|---|---|
| T-cell surface glycoprotein CD3 | Inhibitor | Lung cancer [ICD-11: 2C25.Z]; Gastrointestinal cancer [ICD-11: 2C11.Z] | Kd: 77 nM | Micromet; Amgen | [1] , [2] | |
| Epithelial cell adhesion molecule | Inhibitor | Lung cancer [ICD-11: 2C25.Z]; Gastrointestinal cancer [ICD-11: 2C11.Z] | Kd: 16 nM | Micromet; Amgen | [1] , [2] | |
| Clinical Trial Information of This SBP | ||||||
|---|---|---|---|---|---|---|
| NCT00635596 | Click to show the Detail | |||||
| Indication | Locally Advanced, Recurrent or Metastatic Solid Tumor | |||||
| Phase | Phase I | |||||
| Title | An Open-label, Multi-center Dose Escalation Phase I Study to Investigate the Safety and Tolerability of a Continuous Infusion of the Bispecific T-cell Engager (BiTE)?MT110?in Locally Advanced, Recurrent or Metastatic Solid Tumors Which Commonly Express EpCAM and Are Not Amenable to Curative Treatment | |||||
| Status | Completed | |||||
| Sponsor | Amgen Research (Munich) GmbH | |||||